


Anti-PCSK9 Rabbit Polyclonal Antibody

Proprotein convertase subtilisin/kexin type 9 · Neural apoptosis-regulated convertase 1 · NARC-1

Gene: PCSK9 UniProt: Q8NBP7 Host: Rabbit Clonality: Polyclonal

Product Image



— Western Blot (1-panel validation)

Actual Western blot validation for anti-PCSK9 rabbit polyclonal antibody. 1-panel validation across domain-specific antibody clones — each panel labeled with its catalog number and target domain. Reducing conditions; 10–20 µg/lane on 7.5–10% SDS-PAGE.

Image placeholder — Immunohistochemistry

— Immunohistochemistry

Suggested image: IHC staining of relevant FFPE tissue section using this antibody at the validated dilution. Include a pre-immune serum negative control alongside. Counterstain: hematoxylin. Scale bar: 100 µm.

Key Product Facts

Supplier	Triple Point Biologics, Inc. (Sudbury, Ontario, Canada)
Product Name	Anti-PCSK9 Rabbit Polyclonal Antibody
Gene Symbol	PCSK9
Alternative Names	Proprotein convertase subtilisin/kexin type 9 · Neural apoptosis-regulated convertase 1 · NARC-1
UniProt ID	Q8NBP7
Host Species	Rabbit
Clonality	Polyclonal
Isotype	IgG
Concentration	—
Purity	>95% (affinity purified)
Pack Size	100 µg
Validated Application	Western Blot (WB)
Recommended Dilution	WB 1:1000 · IHC 1:200 · IF 1:500
Species Reactivity	Human
Immunogen Type	—
Conjugation	Unconjugated
Buffer / Preservatives	PBS, 0.02% sodium azide, 50% glycerol
Website	triplepointbiologics.com/anti-pcsk9-rabbit-polyclonal-antibody

Available Domain-Specific Variants

Triple Point Biologics produces antibodies to defined structural domains of PCSK9. Each variant is directed at a specific structural region of the protein. Exact peptide sequences are proprietary; each variant is validated for the applications listed.

Domain / Variant	Epitope Region (approx. residues)	Cat. No.	Availability
—	—	RP-PCSK9	In catalog
—	C-terminal CHRD	RP4PCSK9	In catalog

Applications & Recommended Dilutions

App.	Species	Dilution Range	Notes
WB	Human	1:1000	Validated dilution per Triple Point Biologics. Optimize per lot and application in each laboratory.
IHC	Human	1:200	Validated dilution per Triple Point Biologics. Optimize per lot and application in each laboratory.
IF	Human	1:500	Validated dilution per Triple Point Biologics. Optimize per lot and application in each laboratory.

Optimal dilutions should be determined by each laboratory for each application. Triple Point Biologics antibodies include a peptide-neutralized negative control aliquot for specific-signal confirmation.

Storage & Handling

Short-term Storage	+4°C (1–2 weeks)
Long-term Storage	-20°C long-term; 4°C short-term (≤1 month); avoid repeated freeze-thaw
Shipping Conditions	Shipped in styrofoam cooler on blue ice
Hazard Warning	Product may contain Sodium Azide — POISONOUS AND HAZARDOUS. Handle by trained personnel only.
Shelf Life	12 months from date of receipt under recommended conditions

Published Validation — Key References

UniProt Consortium. (2023) UniProt: the Universal Protein Knowledgebase in 2023. Nucleic Acids Res. 51(D1):D523–D531.

Rawlings ND, Barrett AJ, Thomas PD, Huang X, Bateman A, Finn RD. (2018) The MEROPS database of proteolytic enzymes, their substrates and inhibitors in 2017. Nucleic Acids Res. 46(D1):D624–D632.

Target Background

Rabbit polyclonal antibody against PCSK9 (Proprotein Convertase Subtilisin/Kexin type 9). PCSK9 is a secreted subtilisin-family serine protease widely known as the master regulator of LDL receptor (LDLR) turnover. Circulating PCSK9 binds the LDLR extracellularly and directs the LDLR-PCSK9 complex to lysosomal degradation, elevating serum LDL cholesterol.

Gain-of-function mutations in PCSK9 cause autosomal dominant familial hypercholesterolemia, while loss-of-function variants (particularly R46L, Y142X, C679X) protect against cardiovascular disease. This inverse genetics has driven development of

therapeutic monoclonal antibodies (evolocumab, alirocumab, tafalectimab) and siRNA (inclisiran) that lower LDL cholesterol by 50–70%. Beyond LDLR regulation, PCSK9 modulates VLDL, apolipoprotein B secretion, hepatocyte inflammation, and possibly innate immunity via CD36 and other cell-surface receptors.

The RP4 clone targets the C-terminal Cys/His-rich domain (CHRD), which mediates PCSK9 self-oligomerization and enhances LDLR binding avidity. This domain is preserved across mammals with >90% sequence identity.

Applications: Western blot validated (RP4). Recommended positive controls: HepG2 hepatocellular lysate (endogenous), transfected HEK293 with human PCSK9, or human serum (dilute 1:20). The pro-form (~74 kDa) is autocleaved to the mature form (~62 kDa) in the ER; both are detectable with this antibody.

Immunogen: Synthetic peptide corresponding to the C-terminal CHRD of human PCSK9 (UniProt Q8NBP7).

Reactivity: Human confirmed; mouse and rat cross-reactivity predicted.

Gene & Protein Reference

Gene Symbol	PCSK9
HGNC	—
NCBI Gene ID (Human)	—
NCBI Gene ID (Mouse)	—
Ensembl	—
OMIM	—
UniProt (Human)	Q8NBP7
UniProt (Mouse)	—
Protein Family	Serine Proteinase
Predicted MW	See UniProt entry
Observed MW	—
Chromosome	—
Paralogue	—
Key Substrates	—
Activated by	—
Inhibited by	—

About Triple Point Biologics

With over 30 years dedicated to antibody production, Triple Point Biologics is a Canadian company and the premier resource for proteinase and proteinase inhibitor research. Products have been cited in thousands of peer-reviewed publications.

The domain-specific antibody strategy — available in standard, ATK, SPA, and GSK kit formats — delivers predefined epitopes, built-in peptide-neutralized negative controls, and superior specificity for WB and IHC.

Website: www.triplepointbiologics.com

FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES.

Product specifications subject to change. Contact Triple Point Biologics for current product and availability information.